Acute lymphoblastic leukaemia: who works on it

One card per institution. Pick a target to see only the groups that work on it.

• All targets
• CD19 122
• CD22 33
• ABL1 10
• KMT2A 8
• CD20 8
• TP53 0
• AKT 0
• BCL-2 3
• PI3K 0
• CD123 5
• JAK 2
• CD38 4
• PD-1 3
• RUNX1 0
• mTOR 0
• NPM1 4
• BCMA 4
• NOTCH1 0
• CXCR4 1
• PTEN 0
• CTNNB1 0
• EGFR 0
• HDAC 0
• IDH 0
• MYC 0
• RAS 0
• STAT3 0
• AMPK 0
• CD30 0
• CD40 0
• CD47 0
• ERK 0
• FGFR 0
• MAPK 0
• MDM2 0
• PD-L1 0
• CD33 1
• FLT3 0
• IL-1 0
• IL-17 0
• IL-6 0
• KRAS 0
• MEK 0
• PPAR 0
• RANKL 0
• RB1 0
• TYK2 0
• ALK 0
• AXL 0
• BRCA1 0
• BRD4 0
• BTK 0
• CDK4/6 0
• CDKN2A 0
• CTLA-4 0
• EZH2 0
• FAK 0
• FTO 0
• GPRC5D 1
• GPX4 0

19 of 19+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-ERC-POC

  SMART-SMAPs: a new paradigm of cell-free cytotoxic immunotherapy for resistant CLL

  Universita Degli Studi di Siena· Siena, Italy· EU contribution €150,000· until Mar 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-RIA

  TOWARDS THE ELIMINATION OF ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN THROUGH IDENTIFICATION OF THEIR ENVIRONMENTAL CAUSES (ELI-ALL)

  Centre International de Recherche Sur Le Cancer· Lyon 7eme, France· EU contribution €6,502,240· until Aug 2031· 12 countries

• European Commission (Horizon Europe) · HORIZON-RIA

  THERAPEUTIC ANTIBODIES NEUTRALIZING ALL THE ORTHOPOXVIRUS INFECTIOUS FOR HUMANS, INCLUDING SMALLPOX (THANATOS)

  Commissariat A L Energie Atomique Et Aux Energies Alternatives· Paris, France· EU contribution €13,557,641· until Aug 2031· 6 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Role of RAS mutant subclones in the development of High Hyperdiploid B-ALL (RasWayToALL)

  Vib Vzw· Zwijnaarde - Gent, Belgium· EU contribution €200,400· until Jun 2028

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-CSA

  Science, Innovation, Health, Earth, And Life Technologies for ALL (SCIENCE4ALL)

  Istinye University· Istanbul, Türkiye· EU contribution €350,000· until Jun 2028

• European Commission (Horizon Europe) · HORIZON-CSA

  OUR SCIENCE - MAKING SCIENCE A SHARED JOURNEY FOR ALL (OUR_SCIENCE_26-27)

  Rannsoknamidstod Islands· Reykjavik, Iceland· EU contribution €349,226· until May 2028

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  PANDEMIC PREPAREDNESS THROUGH INTRANASAL ADMINISTRATION OF BROADLY EFFECTIVE MONOCLONAL ANTIBODIES AGAINST ALL INFLUENZA STRAINS (PanFlu)

  Leyden Laboratories Bv· Leiden, Netherlands· EU contribution €2,499,999· until Oct 2027

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Relapse in T-ALL: Resistant Clones and Therapeutical Options (RETRO)

  Fundacion Para la Gestion de la Investigacion En Salud de Sevilla· Sevilla, Spain· EU contribution €181,153· until Aug 2027

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  DUO 4 ALL

  Croivalve Limited· Dublin, Ireland· EU contribution €2,493,375· until Jan 2027

• European Commission (Horizon Europe) · HORIZON-EIC-ACC-BF

  The first IVDR-approved commercial software solutions for AI-powered RNA-based companion and precision cancer diagnostics of acute myeloid leukaemia and bladder cancer (QIandQD)

  Qlucore Ab· Lund, Sweden· EU contribution €2,491,650· until Apr 2027

  The disease is named only in the funder's project summary, not in the title.

10 of 13 running projects, newest first. Listed amounts together: €62.2m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  NCT05032183· M.D. Anderson Cancer Center· Updated 11 Aug 2025

  “The study was terminated early due to slow enrollment.”Registry text, quoted unchanged. Source

• Withdrawn

  Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies

  NCT05513612· Shanghai Pudong Hospital· Updated 1 Mar 2023

  “The study is not initiated and we want it to be withdrawn.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

  NCT04318678· St. Jude Children's Research Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 6
• Mendelian Randomization Analysis 4
• CRISPR-Cas Systems 5
• Gene Expression Profiling 27
• Sequence Analysis, RNA 2
• Whole Genome Sequencing 1
• Exome Sequencing 1
• Proteomics 7
• Metabolomics 4
• Flow Cytometry 40
• Immunohistochemistry 6
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 50
• Magnetic Resonance Imaging 14
• Machine Learning 11
• Deep Learning 8
• Cohort Studies 26
• Genome-Wide Association Study 8

• Long-term trends in mortality of leukemia in Asia from 1992 to 2021: An age-period-cohort and population-based observational analysis of the Global Burden of Disease study 2021.

  Medicine (Baltimore), Aug 2026

• Characterization of Genetic Etiologic Factors for Pediatric Acute Lymphoblastic Leukemia in Large Childhood Cancer Survivorship Cohorts.

  Cancer Epidemiol Biomarkers Prev, Jul 2026

  Zhaoming Wang

• Relapse Thresholds (12/24 Mo) Define Survival Disparity in Pediatric B-ALL.

  Am J Hematol, Jul 2026

• Palliative Analgesia in Patients With Childhood Cancer: A Retrospective Cohort Study.

  Pain Pract, Jul 2026

• Operative management of pediatric radiation-induced cavernous malformations: insights from a single-center cohort.

  Childs Nerv Syst, Jun 2026

• Maternal Thyroid Diseases, Medication Use and Childhood Cancer Risks in Offspring: A Population-Based Cohort Study in Denmark.

  Int J Cancer, Jun 2026

  Julia E Heck

• Impact of treatment for childhood acute lymphoblastic leukemia on later education, paid labor, and sickness- or activity compensation: A registry study from Sweden.

  Cancer Epidemiol, Apr 2026

• Philadelphia chromosome-negative but BCR::ABL1-positive acute lymphoblastic leukemia: a real-world multicenter cohort study.

  Int J Hematol, Apr 2026

• TCF3::HLF-positive B-ALL: integrated clinical and molecular characterization of 34 cases from a single-center cohort.

  Br J Cancer, Apr 2026

• Molecular and Pharmacogenetic Marker Evaluation in Relation to the Toxicity and Clinical Response of Acute Lymphoblastic Leukemia Treatment in Indian Children (MPGx-INDALL): Protocol for a Prospective Observational Cohort Study.

  JMIR Res Protoc, Mar 2026

See which targets of this disease your abstract mentions, and go to the people working on them.